Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Allurion Technologies ( (ALUR) ).
On March 2, 2026, Allurion Technologies announced that it had received a delisting notice from the New York Stock Exchange after failing to meet the exchange’s continued listing standards requiring at least $50 million in stockholders’ equity or market capitalization. The company had previously been notified of noncompliance on August 29, 2024, but its common stock and warrants are expected to continue trading on the NYSE during an appeal process, provided it meets other listing requirements.
Allurion said it will appeal the NYSE staff decision to a review committee while executing a plan to regain compliance or secure a listing on another U.S. exchange. The strategy includes capital-raising efforts, negotiations with creditors and security holders, and a previously announced deal to swap all outstanding debt into preferred stock at a premium, alongside a warrant inducement transaction completed on February 24, 2026.
The most recent analyst rating on (ALUR) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Allurion Technologies stock, see the ALUR Stock Forecast page.
Spark’s Take on ALUR Stock
According to Spark, TipRanks’ AI Analyst, ALUR is a Neutral.
Overall score is held back primarily by weak financial performance: contracting revenue, large ongoing losses, heavy cash burn, and negative equity. Offsetting factors include improving cost control and constructive FDA/regulatory and balance-sheet restructuring progress discussed on the earnings call, plus moderately positive technical momentum. Valuation remains difficult to support due to negative earnings and no dividend yield provided.
To see Spark’s full report on ALUR stock, click here.
More about Allurion Technologies
Allurion Technologies, Inc. is a medical technology company focused on metabolically healthy weight loss solutions, including its Allurion Gastric Balloon System and Smart Capsule. The company targets the obesity treatment market and positions itself as a pioneer in combining device-based therapies with emerging pharmaceutical approaches such as GLP-1 therapies.
Average Trading Volume: 2,671,707
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.37M
Find detailed analytics on ALUR stock on TipRanks’ Stock Analysis page.